Abstract
8053Background: Treatment options for patients (pts) with relapsed/refractory (RR) AL amyloidosis are limited. Daratumumab (dara) has been approved as monotherapy (DMT) or combination therapy (DCT) for multiple myeloma (MM). Data for dara-based therapy (DBT) in AL are sparse. Methods: We studied pts with RR AL without coexisting MM seen at Mayo Clinic from 11/2015 to 02/2018 & treated with DBT. Hematologic response (HR) & organ response (OR) were defined per Consensus criteria. All time to event analyses were done from the time of DBT initiation. Pts with dFLC < 4 mg/dL at the time of start of DBT were considered non evaluable (NE) for HR other than disease progression. DCT included dara, pomalidomide & dexamethasone (dex) (35%), dara, lenalidomide & dex (26%), dara, bortezomib & dex (22%) & other DBT regimens (17%). Results: 45 pts (DMT, n = 22; DCT, n = 23) received DBT; median age at DBT initiation was 64 years (range: 46-82). Data for HR assessment were available in 44 pts & 31 were evaluable for HR. ...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
